Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
14 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
SIMABS from Diepenbeek, company number BE0732709096, closed financial year 2025 with a result of € -1.5 million after tax. For that financial year SIMABS recorded a gross margin of € -129,335 and equity of € 1 million. Compared with financial year 2024, the result moved from € -986,869 to € -1.5 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 1 million
▲ € 1.3 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.5 million
▼ 49 % more loss than in 2024
Profit after tax over the fiscal year.
€ 970,589
▲ € 807,823 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.7 million.
People and assets in 2025
11.4
▲ 4.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.1 million
▲ 65% vs 2024
€ 95,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 146,708
▼ 49% vs 2024
Of which on lease € 146,708.
Debts at end 2025
€ 390,466
▼ 60% vs 2024
€ 128,736 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1.1 million
▲ € 1 million vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 104,043
▲ 41% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -236,868 | € 121,285 | € -105,189 | € -129,335 | ▼ € 24,146 |
| Profit after taxes | € -768,099 | € -453,195 | € -986,869 | € -1,474,700 | ▼ € 487,832 |
| Equity | € 271,415 | € 649,820 | € -337,049 | € 1,003,251 | ▲ € 1.3 million |
| Total debts | € 915,689 | € 776,460 | € 1,447,927 | € 1,665,523 | ▲ 15% |
| Cash | € 342,342 | € 672,241 | € 162,766 | € 970,589 | ▲ € 807,823 |
| Retained profit | € -803,585 | € -1,256,780 | € -2,243,649 | € -3,718,349 | ▼ € 1.5 million |
| Bank debt | € 843,612 | € 601,333 | € 986,526 | € 390,466 | ▼ 60% |
| Balance sheet total | € 1,187,104 | € 1,426,280 | € 1,110,878 | € 2,668,774 | ▲ 140% |
| Employees (FTE) | 4.4 | - | 7.3 | 11.4 | ▲ 4.1 |
Key figures of SIMABS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SIMABS?
What happened at SIMABS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1.5 million. Source: NBB ↗
- Chemsciences Middle East Fzc became a director. NBB
- Pilot Biologix BV BV became a director. NBB
- QbD Growth BV BV became a director. NBB
- Amber Vandecruys became a director. NBB
- Oak Projects BV BV stepped down as director. NBB
- Metatron Holding NV NV became a director. NBB
- Metatron Holding NV NV stepped down as director. NBB
In short
From € 768,099 loss in 2022 to € 1.5 million loss in 2025.
Paid € 4,237 in corporate taxes since 2022.
A new publication or filing at SIMABS? We notify you, reason included.
Follow SIMABSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of QbD Growth, Pilot Biologix, Metatron Holding, Oak Projects, NEVENCO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
SIMABSBehind SIMABS are Chemsciences Middle East Fzc, Pilot Biologix BV BV, QbD Growth BV BV, Eye-Tec BV BV and Amber Vandecruys. The shares are held by QbD Growth (37.1%), Pilot Biologix (18.5%), Metatron Holding (10.6%), Oak Projects (2.9%) and NEVENCO.
Directors
According to the 2025 annual accounts
Director · represented by Amit Tibrewala
since 2025
Director · represented by Koen Dierckx
since 2025
Director · represented by Bart Van Acker
Also active at: QbD RepS, QbD Clinical Holding, QbD Clinical, TURNSTONE COMMUNICATIONS
since 2025
Director · represented by Bram Keymolen
since 2023
Amber Vandecruys
Director
since 2025
Director · represented by Joachim Vandeput
since 2023 · until 2025
Director · represented by Jo Nelissen
Also active at: Poels, ABN KLIMATISATIE, ABN Cleanroom Technology, KENWELD, DADDY KATE, I-PLACE, Aionis
since 2025 · until 2025
Director · represented by Bart Van Acker
Also active at: Qarad EC-REP, QARAD, QbD Wallonia, QbD Clinical Holding, HEALTHTOMARKET, Monkeys Not Donkeys, QbD Flanders, TURNSTONE COMMUNICATIONS
since 2023 · until 2025
Nicolas Vandermarliere
Director
since 2023 · until 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Agoralaan Abis
3590 Diepenbeek
Wetenschapspark 9
3590 Diepenbeek
Active since 25 September 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
All companies at this address →Clinitude
€ 419,430 gross margin · 2025
FOx Biosystems
€ -763,895 gross margin · 2023
Highstar Engineering
€ -41,079 gross margin · 2024
IDEA FAMILY
€ -3,258 gross margin · 2025
BIOKEY
€ -25,987 gross margin · 2025
+9 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
simabs.com
Registered
2018-12-29
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2026-12-29
Website info
Features
Security
Network
Details
- Company number
- 0732.709.096
- VAT number
- BE 0732.709.096
- Registered office
- Agoralaan Abis, 3590 Diepenbeek
- Names & denominations
- SIMABS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 August 2019
- Peppol
- Active · Active since 25 Nov 2025
- Contact
- simabs.com [email protected]
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van geneesmiddelen
Vervaardiging van overige farmaceutische producten
Vervaardiging van farmaceutische grondstoffen